BML Capital Management’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

BML Capital Management’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,654,053	Closed	-$11M	–	35
2024 Q1	$11M	Buy	3,654,053 +404,045	+12%	+$1.25M	7.25%	6
2023 Q4	$9.88M	Hold	3,250,008	–	–	7.48%	4
2023 Q3	$9.23M	Buy	3,250,008 +8	+0%	+$22	8.48%	4
2023 Q2	$8.45M	Buy	3,250,000 +103,704	+3%	+$217K	7.6%	3
2023 Q1	$5.73M	Buy	+3,146,296	New	+$5.11M	4.95%	5

BML Capital Management's CYT Position: Q2 2024 in Review

BML Capital Management sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2024, closing a stake of 3,654,053 shares — an estimated $11M sold.

BML Capital Management first reported a position in CYT in Q1 2023 and held it in 5 quarters. The position peaked at $11M in Q1 2024. 0 funds tracked by Wall St. Rank hold CYT as of Q2 2024.

BML Capital Management reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
BML Capital Management sold 3,654,053 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $11M.
BML Capital Management first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
BML Capital Management's Cyteir Therapeutics, Inc. Common Stock position peaked at $11M in Q1 2024.
0 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.